New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Abbvie (ABBV) PT Raised to $97 at Piper Sandler
February 7, 2020 1:23 PM ESTPiper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $97.00 (from $95.00) while maintaining a Overweight rating following results.
... MoreAbbVie (ABBV) Sees Strong Gains Post-EPS
February 7, 2020 12:39 PM ESTAbbVie (NYSE: ABBV) seeing strong gains following results this morning. Shares up 5.5%.
... More